Prof. Stephen Johnston discusses the recent phase III MonarchE trial, the data presented at the Virtual 2020 ESMO Congress, and the role of abemaciclib in the treatment of HR+, HER2-, high-risk early breast cancer. Prof Johnston presented the late-breaking abstract ‘Abemaciclib in high risk early breast cancer’ (LBA5_PR) during the Virtual 2020 ESMO Congress, 19–21 September 2020.
Questions
- What are the unmet needs in the treatment of HR-positive, HER2-negative early breast cancer and what factors influence the likelihood of recurrence? (0:12)
- Could you tell us a little about the aims, design and findings of the MonarchE clinical trial? (1:15)
- What is the clinical significance of these findings and how are they likely to impact on future clinical practice? (2:45)
- What other agents that could be effectively combined with CDK4/6 inhibitors, beyond endocrine therapy? (4:09)
- What will be the next steps in the clinical development of abemaciclib in breast cancer therapy? (6:02)
Speaker Disclosures: Stephen Johnston has provided consultancy for Novartis, Pfizer, Eli Lilly, Puma Biotechnology; has received speaker honoraria from Eisai, AstraZeneca, Eli Lilly, Novartis, Pfizer, Roche; and has received research funding for his institution from Pfizer, Puma Biotechnology, Eli Lilly, AstraZeneca, Novartis, Roche/Genentech.
Support: Interview and filming supported by Touch Medical Media Ltd. The MonarchE trial was sponsored by Eli Lilly and Company.
Filmed in coverage of the Virtual 2020 ESMO Congress.
